X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 44.4 25.8 172.4% View Chart
P/BV x 3.9 3.8 103.0% View Chart
Dividend Yield % 0.3 0.6 54.2%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
SUN PHARMA
Mar-17
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs622842 73.9%   
Low Rs458572 80.1%   
Sales per share (Unadj.) Rs181.9131.6 138.2%  
Earnings per share (Unadj.) Rs12.932.7 39.4%  
Cash flow per share (Unadj.) Rs29.338.0 77.2%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.40.5 74.8%  
Book value per share (Unadj.) Rs155.7152.7 101.9%  
Shares outstanding (eoy) m804.512,399.26 33.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.4 55.3%   
Avg P/E ratio x42.021.6 194.0%  
P/CF ratio (eoy) x18.418.6 98.9%  
Price / Book Value ratio x3.54.6 74.9%  
Dividend payout %15.510.7 145.2%   
Avg Mkt Cap Rs m434,5161,696,877 25.6%   
No. of employees `00023.017.5 131.6%   
Total wages/salary Rs m26,33849,023 53.7%   
Avg. sales/employee Rs Th6,349.118,028.3 35.2%   
Avg. wages/employee Rs Th1,143.02,798.8 40.8%   
Avg. net profit/employee Rs Th449.34,479.5 10.0%   
INCOME DATA
Net Sales Rs m146,302315,784 46.3%  
Other income Rs m2,2876,232 36.7%   
Total revenues Rs m148,589322,016 46.1%   
Gross profit Rs m24,758100,893 24.5%  
Depreciation Rs m13,22912,648 104.6%   
Interest Rs m1,5943,998 39.9%   
Profit before tax Rs m12,22290,479 13.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-7099 -70.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,79812,116 14.8%   
Profit after tax Rs m10,35478,462 13.2%  
Gross profit margin %16.931.9 53.0%  
Effective tax rate %14.713.4 109.8%   
Net profit margin %7.124.8 28.5%  
BALANCE SHEET DATA
Current assets Rs m87,370329,537 26.5%   
Current liabilities Rs m33,081178,870 18.5%   
Net working cap to sales %37.147.7 77.8%  
Current ratio x2.61.8 143.4%  
Inventory Days Days8779 110.1%  
Debtors Days Days6283 74.8%  
Net fixed assets Rs m111,567204,766 54.5%   
Share capital Rs m1,6092,399 67.1%   
"Free" reserves Rs m123,645363,997 34.0%   
Net worth Rs m125,254366,397 34.2%   
Long term debt Rs m36,45414,361 253.8%   
Total assets Rs m209,532614,102 34.1%  
Interest coverage x8.723.6 36.7%   
Debt to equity ratio x0.30 742.5%  
Sales to assets ratio x0.70.5 135.8%   
Return on assets %5.713.4 42.5%  
Return on equity %8.321.4 38.6%  
Return on capital %8.524.8 34.2%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06644,118 115.7%   
Fx outflow Rs m17,67824,484 72.2%   
Net fx Rs m33,38819,634 170.1%   
CASH FLOW
From Operations Rs m23,82470,822 33.6%  
From Investments Rs m-13,127-42,216 31.1%  
From Financial Activity Rs m-13,239-22,854 57.9%  
Net Cashflow Rs m-2,4786,107 -40.6%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  MERCK LTD  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Power Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 19, 2018 03:33 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS